Edwards Lifesciences Corp (EW)

Interest coverage

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Earnings before interest and tax (EBIT) (ttm)	US$ in thousands	1,534,100	1,581,800	1,565,800	1,698,100	1,748,500	1,675,100	1,663,000	1,745,600	1,690,300	1,667,300	1,634,800	923,000	897,600	857,000	793,500	1,230,700	1,146,800	830,700	785,300	769,900
Interest expense (ttm)	US$ in thousands	-1,100	6,800	13,700	5,500	16,300	8,900	2,800	2,900	2,600	17,900	17,900	18,700	22,900	35,000	37,000	37,600	35,100	9,000	6,700	4,300
Interest coverage		—	232.62	114.29	308.75	107.27	188.21	593.93	601.93	650.12	93.15	91.33	49.36	39.20	24.49	21.45	32.73	32.67	92.30	117.21	179.05

December 31, 2023 calculation

Interest coverage = EBIT (ttm) ÷ Interest expense (ttm)
= $1,534,100K ÷ $-1,100K
= —

The interest coverage ratio for Edwards Lifesciences Corp showed a significant increase in Q1 2022, reaching a high level of 2,357.43. This indicates that the company was able to cover its interest expenses 2,357.43 times over with its earnings before interest and taxes (EBIT) in that quarter. Unfortunately, without data for the subsequent quarters up to Q4 2023, it is difficult to provide a complete trend analysis to assess the company's ability to meet its interest obligations over time. More recent data would be needed to evaluate the company's current financial health and management of its interest expenses.